Balaji Amines LtdQ1 FY26Chemicals & Petrochemicals

Balaji Amines Ltd

Q1 FY26 Earnings Call Analysis

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Revenue guidance

Category 2

→The company targets around 25% to 30% volume growth by end of FY27 compared to current levels.
→For the current year, a conservative volume growth of 10% to 15% is expected.
→Growth drivers include new products: Dimethyl Ether (DME), Acetonitrile (ACN), and N-Methyl Morpholine (NMM).
→DME plant commissioning expected in Q1 FY27, with utilization likely at 30%-40% in the current year and up to 80%-90% in coming years.
→Balaji Specialty Chemicals subsidiary is investing significantly, with INR 350-400 crores capex planned in phase 1, supporting expansion.
→Revenue target of INR 3,000 crores by FY28, supported by expanded specialty product portfolio and DME.
→EBITDA margins are expected to be sustainable between 22%-23% alongside volume growth.
→Continuous ramp-up expected as battery industries and other end markets stabilize, supporting further volume increases.

Category 3

→Management expects 20% to 30% volume growth in the coming financial year (FY27), driven by new plants such as Dimethyl Ether (DME), Acetonitrile, and N-Methyl Morpholine (NMM), as well as increased demand from battery industries.
→EBITDA margins are anticipated to sustain at around 22% to 23%.
→The company aims to increase utilization of the DME plant to 30%-40% in FY27, with further ramp-up to 50%-60% by year-end, reaching 80%-90% in subsequent years.
→Consolidated EBITDA grew 11% in FY26, with EBITDA margin improving from 19% to 20%, and PAT margin improving from 11% to 12%.
→EPS for Q4 FY26 stood at INR 19.99, showing improvements over previous quarters.
→The company plans steady operational improvements and capacity expansions, expecting these to support revenue growth up to INR 2,000 crores by FY28.
→They will continue prudent raw material management to maintain margins amid price volatility.

Get access to all 5 sections — revenue, margin, fundraise, orderbook, and capex — for Balaji Amines Ltd and 1,400+ other companies.

→The company has not provided any definitive update on an IPO or stake increase; it's "too early" to discuss IPO plans.
→Any decision on IPO or increasing stakes will depend on the market introduction of products and board approvals.
→Current consolidated debt is INR133 crores, mainly due to ongoing expansion activities.
→For ongoing expansions, the company has planned capex of around INR275 to INR290 crores for FY27, funded internally or through current financial position (no explicit mention of new fundraising).
→No mention of any new equity or debt fundraising in the transcript; focus seems to be on completing expansions and utilizing existing capacities.
→The management assures disciplined capital management and a strong balance sheet without indicating immediate plans for fresh fundraising.

→The company is in the process of expanding its product range with new products such as Dimethyl Ether (DME), Acetonitrile, and N-Methylmorpholine (NMM).
→For DME, the plant is commissioned but awaiting road transport permission; production is ongoing, and once permission is granted, utilization is expected to increase to 30-40% in the current year and up to 80-90% in later years.
→Prospective customers for DME have been approached, and trial shipments with 500 kg cylinders are underway to secure bulk orders.
→Some battery chemical products have received commercial orders, but full-scale demand depends on battery manufacturers ramping up operations.
→The greenfield and brownfield capex projects (e.g., Balaji Specialty Chemicals) are ongoing, with modifications progressing and investor plant visits planned soon.
→No specific numeric order book or pending orders disclosed, but the company indicated growing demand and upcoming volume growth of 20-30% driven by new products and markets.

Yes

→Standalone capex for FY27: Around INR 20 crores balance for 3 products (DME, NMM, ACN), mostly already paid for equipment.
→Balaji Specialty Chemicals subsidiary: Total Phase 1 capex INR 750 crores; INR 350-400 crores planned. For FY27, >INR 100 crores already spent, plus another INR 200-250 crores expected.
→Greenfield and brownfield expansions ongoing; Phase 1 for greenfield partially in production (ethylamine, DMC) with modifications underway for specialty chemicals plant.
→Dimethyl Ether (DME) plant: Commissioning expected in Q1 FY27, pending road transportation permission; capacity ramp-up projected reaching 50-60% by FY27-end, 80-90% in subsequent years.
→Capex combined on consolidated basis for FY27 estimated between INR 275-290 crores.
→Management inviting investors soon to visit plants to witness ongoing expansions.

How does Balaji Amines Ltd rank vs peers in Chemicals & Petrochemicals?

Pro feature

1Balaji Amines Ltd

Rev 2Mar 3

See full Chemicals & Petrochemicals sector rankings

Want more stocks like Balaji Amines Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.